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Introduction
Axons of the central nervous system (CNS) demonstrate no 
functionally signifi  cant regeneration after injury, in contrast to 
those of the peripheral nervous system, which regenerate vig-
orously, leading often to complete functional recovery. This 
lack of regeneration generally results in partial disability or 
complete paralysis after a CNS injury. However, some adult 
CNS axons can grow through a peripheral nerve graft (David 
and Aguayo, 1981), suggesting that the local glial environment 
of the adult CNS is a major cause of the lack of regeneration. 
So far, three major inhibitors—Nogo, myelin-associated gly-
coprotein (MAG), and oligodendrocyte-myelin glycoprotein 
(OMgp)—expressed by oligodendrocytes and myelinated fi  ber 
tracts have been identifi  ed. Interestingly, all these inhibitors 
were found to bind to the Nogo receptor (NgR) in complex 
with p75 or TROY, members of the TNF receptor family, sug-
gesting that they have common signaling pathways (Teng and 
Tang, 2005).
However, some reports suggest that inhibition of these 
molecules alone is insuffi  cient for regeneration after CNS in-
jury (Teng and Tang, 2005). MAG knockout mice exhibited lit-
tle or no enhancement of axonal regeneration in the spinal cord. 
There seems to be some controversy concerning Nogo knock-
out mice and NgR-defi  cient mice. Neither depletion of func-
tional p75 nor administration of a soluble p75-Fc at the lesion 
site promoted regeneration of the injured spinal cord. These 
fi  ndings prompted us to search for new inhibitors.
Repulsive guidance molecule (RGM), which has been 
reported as the 33-kD mass tectum repellent in chick, induces 
the collapse of temporal but not nasal growth cones and guides 
temporal retinal axons in vitro (Stahl et al. 1990; Muller et al., 
1996; Monnier et al., 2002). RGM binds to neogenin, identifi  ed 
as a netrin-1 receptor and homologue of DCC (deleted in co-
lorectal cancer), mediating its repulsive activity toward retinal 
axons (Rajagopalan et al., 2004). During chick development, 
neogenin functions as a dependence receptor, inducing cell 
death in the absence of RGM (Matsunaga et al., 2004). Three 
mouse proteins, homologous to chick RGM, termed mRGMa, 
-b, and -c (Niederkofl  er et al., 2004; Oldekamp et al., 2004; 
Schmidtmer and Engelkamp, 2004) have been reported. Mouse 
RGMa is highly homologous (80% identity) to chick RGM. 
Functional studies in RGMa mutant mice revealed the role of 
RGMa in controlling cephalic neural tube closure (Niederkofl  er 
et al., 2004).
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epulsive guidance molecule (RGM) is a protein im-
plicated in both axonal guidance and neural tube 
closure. We report RGMa as a potent inhibitor of 
axon regeneration in the adult central nervous system 
(CNS). RGMa inhibits mammalian CNS neurite outgrowth 
by a mechanism dependent on the activation of the RhoA–
Rho kinase pathway. RGMa expression is observed in oli-
godendrocytes, myelinated ﬁ   bers, and neurons of the 
adult rat spinal cord and is induced around the injury site 
after spinal cord injury. We developed an antibody to 
RGMa that efﬁ  ciently blocks the effect of RGMa in vitro. 
Intrathecal administration of the antibody to rats with tho-
racic spinal cord hemisection results in signiﬁ  cant axonal 
growth of the corticospinal tract and improves functional 
recovery. Thus, RGMa plays an important role in limiting 
axonal regeneration after CNS injury and the RGMa an-
tibody offers a possible therapeutic agent in clinical con-
ditions characterized by a failure of CNS regeneration.
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We reported that up-regulation of RGMa was observed at 
the lesioned or damaged site after spinal cord injury (SCI) in rats 
(Schwab et al., 2005a) and focal cerebral ischemia and traumatic 
brain injury in humans (Schwab et al., 2005b). In addition, neo-
genin and other netrin-1 receptors are constitutively expressed 
by neurons and glial cells in the adult rat spinal cord (Manitt et al., 
2004). These fi  ndings prompted us to hypothesize that RGMa 
may play a role in inhibiting axonal regeneration after CNS 
  injury. In this study, we show that RGMa inhibits neurite out-
growth in postnatal cerebellar neurons in vitro. RGMa expres-
sion is induced after SCI in rats at the lesion site, in the developing 
scar tissue, and on the myelinated fi  ber tracts. Local administra-
tion of a neutralizing antibody to RGMa signifi  cantly facilitates 
locomotor improvement and axon regeneration after SCI.
Results
RGMa inhibits neurite outgrowth by 
a mechanism dependent on the activation 
of the RhoA–Rho kinase pathway
We fi rst asked whether RGM contributes to the inhibition of 
mammalian CNS neurite outgrowth in vitro. Cerebellar granule 
neurons were used because they express the receptor for RGMa 
(Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200508143/DC1). We cultured cerebellar granule neurons 
from postnatal rats (postnatal days 7–9) on confl  uent mono-
layers of either CHO cells expressing rat RGMa (RGMa-CHO 
cells) or control CHO cells for 24 h and assessed the neurite 
outgrowth rate (the coculture assay). Neurite  outgrowth was 
Figure 1.  Effects of membrane bound/diffusible RGMa on neurons. (A) The membrane bound form of RGMa inhibits neurite outgrowth by a Rho-kinase–
dependent mechanism. The cerebellar neurons were cultured for 24 h on control CHO cells (control) or RGMa-CHO cells (RGMa) in the presence or 
  absence of 10 μM Y27632. (B) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with 
RGMa (t test). (C) RGMa activates RhoA. The cerebellar neurons were treated for 10 min with conditioned media, derived from PI-PLC treatment of control 
CHO or RGMa-CHO cells. The active fraction of RhoA along with total RhoA was detected by Western blot. (D) Immunostaining of the supernatant from 
control/RGMa CHO cells treated with or without PI-PLC. The protein was detected by an anti-HA antibody. Coomassie staining was performed for the same 
samples. (E) The soluble form of RGMa inhibits neurite outgrowth. Neurons were cultured on PLL-coated chamber slides for 12 h in the conditioned media 
from untreated control CHO cells, PI-PLC–treated control CHO cells, untreated RGMa-CHO cells, or PI-PLC–treated RGMa-CHO cells. (F) Mean length of 
the longest neurite per neuron. *, P < 0.01 compared with the control CHO PI-PLC(+) (t test). (G) PI-PLC treatment reverses the inhibitory effect of RGMa-
CHO cells. Neurons were cultured for 24 h on control/RGMa CHO cells pretreated with or without PI-PLC. (H) Mean length of the longest neurite per neuron. 
*, P < 0.01 compared with the control CHO PI-PLC(−); **, P < 0.01 compared with RGMa-CHO PI-PLC(−) (t test). There is no signiﬁ  cant difference be-
tween the control CHO PI-PLC(+) and RGMa-CHO PI-PLC(+). (I–L) RGMa inhibits neurite outgrowth by an NgR-independent mechanism. (I) The cerebellar 
neurons were cultured for 24 h on control/RGMa CHO cells in the presence or absence of 1 μM NEP1-40. (J) Mean length of the longest neurite per 
  neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + NEP1-40 (t test). There is no signiﬁ  cant difference between 
RGMa and RGMa+NEP1-40. (K) The neurons were cultured on PLL-coated chamber slides for 24 h in the conditioned media from PI-PLC–treated control/
RGMa CHO cells in the presence or absence of 1 μM NEP1-40. (L) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; 
**, P < 0.01 compared with the control + NEP1-40 (t test). There is no signiﬁ  cant difference between RGMa and RGMa + NEP1-40. Data are represented 
as the mean ± SEM of three independent experiments.RGMA, A NOVEL INHIBITOR OF AXONAL REGENERATION • HATA ET AL. 49
signifi  cantly inhibited when grown on RGMa-CHO cells (Fig. 1, 
A and B). To explore the signal transduction mechanism in-
volved in the inhibition of neurite outgrowth, we assessed whether 
the neuronal effects of RGMa are dependent on the small 
GTPase RhoA or its downstream effector, the Rho-associated 
serine/threonine kinase (Rho kinase). We cultured the neurons 
on RGMa-CHO cells in the presence of 10 μM Y27632, a spe-
cifi  c inhibitor of Rho kinase (Uehata et al., 1997), for 24 h and 
observed that the inhibitory activity of RGMa was abolished by 
Y27632 (Fig. 1, A and B). To directly assess whether RhoA is 
involved in the signal transduction of RGMa, the activity of 
RhoA was determined using the RhoA binding domain of the 
effector protein, Rhotekin (Ren et al., 1999; Fig. 1 C). The assay 
revealed that within 10 min after the addition of soluble RGMa 
(see the following paragraph), extracts of the cells contained in-
creased amounts of GTP-RhoA compared with those of the 
control cells. These results suggest that RGMa inhibits neurite 
outgrowth by a mechanism dependent on the activation of the 
RhoA–Rho kinase pathway.
Because rat RGMa, as well as chick RGM (Monnier et al., 
2002), may be a glycosylphosphatidylinositol-linked protein 
that anchors to the cell surface, we examined whether the solu-
ble form of RGMa shows the same activity. The RGMa-CHO 
or control CHO cells were treated with phosphatidylinositol-
 specifi  c PLC (PI-PLC). RGMa was released into the superna-
tant from the RGMa-CHO cells by the treatment as assessed by 
immunodetection on Western blots (Fig. 1 D). We then cultured 
the neurons with the supernatant for 12 h and measured the neu-
rite length (Fig. 1, E and F; the soluble RGMa assay). There was 
no signifi  cant difference in the neurite length between neurons 
cultured in conditioned media from PI-PLC–treated control 
CHO cells and those treated with media from nontreated control 
CHO cells, demonstrating that PI-PLC itself had no effect on 
neurite outgrowth. Neurite outgrowth was signifi  cantly inhib-
ited when the neurons were cultured in conditioned media from 
PI-PLC–treated RGMa-CHO cells, demonstrating that the solu-
ble form of RGMa inhibited neurite outgrowth. Next, we cul-
tured the neurons on PI-PLC–treated RGMa-CHO cells for 24 h 
and observed that the inhibitory activity of RGMa was signifi  -
cantly reduced (Fig. 1, G and H), suggesting that RGMa was 
  released from the cells by the PI-PLC treatment.
The fi  ndings that RGMa activates RhoA and inhibits neu-
rite outgrowth prompted us to examine whether RGMa signals 
via the NgR. To determine whether RGMa binds to the NgR, 
the neurons were cultured for 24 h on RGMa-CHO cells (Fig. 1, 
I and J) or with soluble RGMa (Fig. 1, K and L) in the presence 
or absence of 1 μM NEP1-40 (GrandPre et al., 2002). The in-
hibitory effect of RGMa was not signifi  cantly altered by NEP1-40, 
suggesting that RGMa inhibits neurite outgrowth by an NgR-
independent mechanism.
RGMa protein is expressed in puriﬁ  ed CNS 
myelin and adult rat spinal cord
To examine the protein expression of RGMa in the adult CNS, 
antisera were generated against a synthetic rat RGMa–specifi  c 
peptide and affi  nity purifi  ed. As shown in Fig. S2 A (available 
at http://www.jcb.org/cgi/content/full/jcb.200508143/DC1), 
Figure 2.  The expression of RGMa is induced in response to SCI. (A) West-
ern blot showing the expression of RGMa in puriﬁ  ed CNS myelin. (top) 
  Puriﬁ  ed myelin and the lysates from control/RGMa CHO cells were blotted 
with the anti-RGMa antibody. (bottom) CSPG, puriﬁ  ed MAG-Fc, and puri-
ﬁ  ed myelin were blotted with the anti-RGMa antibody. (B–E) RGMa is 
  expressed in oligodendrocytes and neurons in the rat spinal cord. Fresh 
frozen tissues were obtained for immunohistochemistry from an uninjured 
adult rat spinal cord. Parasagittal sections were stained with anti-RGMa (B) 
or double stained with anti-GFAP and anti-RGMa (C), anti-MOSP and anti-
RGMa (D), or anti-Tuj1 and anti-RGMa (E). (C) Double labeling with GFAP 
and RGMa antibodies shows no colocalization. (D) Double staining with 
the anti-MOSP and anti-RGMa antibody demonstrates that RGMa is ex-
pressed in oligodendrocytes. (E) RGMa immunoreactivity was localized to 
the somata of Tuj1-positive neurons in the gray matter but not to their 
  axons. (F–L) Western blot analysis and immunohistochemistry reveal up-
regulated expression of RGMa after SCI. (F) Western blot demonstrates 
that expression of RGMa is enhanced in the spinal cord tissue 7 d after 
  injury. The protein was detected by an anti-RGMa or anti-actin antibody. 
An uninjured animal served as the control. (G) Injured spinal cord is illustrated 
schematically. A dorsal hemisection was performed at Th9/10. Parasagit-
tal fresh frozen sections of an uninjured control spinal cord and those at 
various postoperative intervals were obtained and used for a time-course 
study of the immunoreactivity to RGMa in the epicenter area (H) and in the 
white matter, 400–500 μm rostral to the epicenter area (I). (J) Double stain-
ing of the same area as H with IB4 and anti-RGMa reveals the presence of 
RGMa-expressing microglia/macrophages. (K) Double staining of the 
same area as I with anti-MOSP and anti-RGMa reveals the presence of 
double-labeled cells (arrows) and non–double-labeled cells (RGMa-positive 
and MOSP-negative cells; arrowheads). (L) Quantiﬁ  cation of the number of 
the cells expressing RGMa and those coexpressing RGMa and MOSP. The 
expression was examined 7 d after SCI. The x axis indicates speciﬁ  c loca-
tions along the rostrocaudal axis of the spinal cord. Data are represented 
as the mean ± SEM of four animals. Bars: (B and H) 100 μm; (C–E and 
I–K) 20 μm.JCB • VOLUME 173 • NUMBER 1 • 2006  50
the anti-HA antibody as well as the anti-RGMa antibody rec-
ognized a protein with an approximate molecular mass of 33 kD 
in the lysates from the CHO cells expressing HA-tagged RGMa 
(RGMa-CHO cells). Identical patterns of immunostaining 
were observed with the anti-HA and anti-RGMa antibody in 
the RGMa-CHO cells. The anti-RGMa antibody detected a 
33-kD band in the purifi  ed CNS myelin (Fig. 2 A) and lysates of
the rat spinal cord (Fig. 2 F). In addition, we confi  rmed that the 
anti-RGMa antibody does not cross-react with chondroitin sul-
fate proteoglycans (CSPGs) or MAG (Fig. 2 A). The specifi  c-
ity of the antibody was further confi  rmed by its depleted 
  immunoreactivity with excess antigen peptide (residues 309–
322 of rat RGMa) in the injured and noninjured adult spinal 
cords (Fig. S2 B).
We then performed immunohistochemistry to investigate 
the distribution pattern of RGMa protein in the adult rat spinal 
cord. RGMa expression was found in both white and gray mat-
ter (Fig. 2 B). Double staining using anti-RGMa and anti–
 myelin/oligodendrocyte-specifi   c protein (MOSP) antibodies 
(Dyer et al., 1991; Beck et al., 1995) showed that RGMa was 
expressed in oligodendrocyte cell bodies and their processes in 
the white matter (Fig. 2 D). In addition, RGMa was localized to 
the somata of neuron-specifi  c β tubulin III protein (Tuj1)–posi-
tive neurons in the gray matter but not to the axons of these cells 
(Fig. 2 E). Double immunostaining with the anti-RGMa anti-
body and the antibody against the glial fi  brillary acidic protein 
(GFAP), an astrocyte marker, showed no colocalization, dem-
onstrating that RGMa is not present in astrocytes (Fig. 2 C). 
Collectively, RGMa is expressed by neurons and oligodendro-
cytes, and its expression pattern in the spinal cord is similar to 
that of Nogo or OMgp (Hunt et al., 2002).
Expression of RGMa is up-regulated after SCI
As our data demonstrate that RGMa inhibits postnatal CNS 
neurons in vitro (Fig. 1) and that RGMa is expressed by neurons 
and oligodendrocytes in the adult spinal cord (Fig. 2, B–E), 
RGMa may play a role in inhibiting axonal regeneration after 
CNS injury. To test this hypothesis, we examined RGMa ex-
pression after SCI. Western blot analysis revealed an increased 
RGMa expression in the spinal cord 7 d after injury (Fig. 2 F). 
We performed immunohistochemistry on fresh frozen sections 
obtained at 6 h and 1, 3, and 7 d after dorsal hemisection of the 
thoracic spinal cord in rats. RGMa expression was induced 
around the injury site after the surgery and was detected in the 
lesion epicenter (Fig. 2, G and H) and the white matter rostral 
(Fig. 2, G and I) and caudal (not depicted) to the lesion site. 
In the epicenter area (Fig. 2 H), the tissue structure appeared nor-
mal 6 h after injury. Subsequently, when degenerative changes 
began to be observed 1–3 d after injury, immunoreactivity for 
RGMa was found in the cells around the lesion site and in areas 
of aberrant extracellular matrix. This extracellular immunoreac-
tivity may be attributable to the degeneration of RGMa-expressing 
cells or to the secretion of RGMa by RGMa-positive cells. 
In the white matter adjacent to the epicenter area (Fig. 2 I), the 
number of RGMa-immunopositive cells and the intensity of 
 immunoreactivity remained almost unaltered after 6 h. However, 
1–3 d after injury, the number of RGMa-positive cells had pro-
gressively increased. At 7 d after injury, there was a signifi  cant 
Figure 3.  The anti-RGMa antibody neutralizes the effect of RGMa and CNS myelin in vitro. (A) The cerebellar neurons were cultured for 24 h on control/
RGMa CHO cells in the presence or absence of 10 μg/ml of the control rabbit IgG or anti-RGMa antibody. (B) Mean length of the longest neurite per 
  neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + control IgG; ***, P < 0.01 compared with RGMa (t test). 
There is no signiﬁ  cant difference between the control + anti-RGMa and RGMa + anti-RGMa. (C) Neurons were cultured on PLL-coated chamber slides for 
24 h in conditioned media from PI-PLC–treated control CHO/RGMa CHO cells supplemented with or without 10 μg/ml of the control IgG or anti-RGMa 
antibody. (D) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with the control + control 
IgG; ***, P < 0.01 compared with RGMa (t test). There is no signiﬁ  cant difference between the control + anti-RGMa and RGMa + anti-RGMa. (E) Neu-
rons were cultured on PLL-coated (control) or PLL + myelin-coated (myelin) chamber slides for 24 h in the presence or absence of 10 μg/ml of the anti-RGMa 
antibody. (F) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.01 compared with myelin; ***, P < 0.01 
compared with the control + anti-RGMa. (G) Immunodepletion of puriﬁ  ed CNS myelin. CNS myelin, depleted myelin, and the protein A beads after immuno-
depletion were blotted with the anti-RGMa antibody. (H) Neurons were cultured on PLL-coated (control), PLL + myelin-coated (myelin), and PLL + depleted 
myelin-coated (d-Myelin) chamber slides for 24 h. (I) Mean length of the longest neurite per neuron. *, P < 0.01 compared with the control; **, P < 0.03 
compared with myelin; ***, P < 0.04 compared with the control. Data are represented as the mean ± SEM of three independent experiments.RGMA, A NOVEL INHIBITOR OF AXONAL REGENERATION • HATA ET AL. 51
increase in the number of RGMa-immunopositive cells in the 
epicenter area.
We performed a double-labeling experiment 7 d after the 
injury to characterize the RGMa-expressing cells. Isolectin B4 
(IB4)– and RGMa-positive cells were detected in the epicenter 
area (Fig. 2 J), suggesting that RGMa is expressed in the 
  microglia/macrophages at the lesion epicenter (Streit, 1990). 
MOSP- and RGMa-positive cells were detected in the white 
matter adjacent to the epicenter area, demonstrating that RGMa 
is expressed in the oligodendrocytes in this area. We found that 
all the MOSP-expressing cells also expressed RGMa, whereas 
RGMa-positive and MOSP-negative cells were detected partic-
ularly around the lesioned site (Fig. 2, K and L). The results of 
the double staining for IB4 and RGMa suggest that an increase 
of these cells is attributable to an increase in the number of 
RGMa-expressing microglia/macrophages in the epicenter area. 
We did not observe GFAP- and RGMa-positive or Tuj1- and 
RGMa-positive cells in the lesion epicenter or in the adjacent 
white matter (unpublished data).
The anti-RGMa antibody neutralizes the 
inhibitory effect of RGMa and CNS myelin
These results suggest that RGMa with its potent inhibitory activ-
ity of neurite outgrowth inhibits axonal regeneration after SCI 
and that blockage of it offers potential for enhanced recovery 
  after SCI. We therefore investigated whether the anti-RGMa 
  antibody could neutralize the inhibitory activity of RGMa in the 
coculture assay (Fig. 3, A and B) and the soluble RGMa assay 
(Fig. 3, C and D). In both assays, the addition of the anti-RGMa 
antibody but not the control IgG signifi  cantly reversed the inhibi-
tory effect of RGMa, demonstrating that the anti-RGMa antibody 
functions as a neutralizing antibody against RGMa in vitro.
As our data demonstrate that RGMa is expressed by the 
CNS myelin, the anti-RGMa antibody may reverse the inhibi-
tory activity of the CNS myelin on neurite outgrowth. To test 
this hypothesis, we cultured neurons on poly-l-lysine (PLL)–
coated or PLL + myelin-coated chamber slides for 24 h in the 
presence or absence of the anti-RGMa antibody (Fig. 3, E and F). 
The inhibitory activity of myelin on neurite outgrowth was 
  partially blocked by the anti-RGMa antibody. We next per-
formed immunodepletion of the CNS myelin with anti-RGMa 
antibody and cultured neurons on depleted myelin-coated 
chamber slides for 24 h. Immunodepletion (Fig. 3 G) partially 
abolished the inhibitory response (Fig. 3, H and I). Thus, myelin-
derived inhibitors except RGMa contribute signifi  cantly to the 
inhibitory response of CNS myelin.
RGMa neutralization leads 
to functional improvement
We then assessed whether endogenous RGMa acts as an inhibi-
tor of axon regeneration in the injured CNS. We transected two 
thirds of the dorsal region of rat spinal cords at the vertebral 
level Th9/10 (lesions 1.8 mm in depth). This resulted in the 
transection of the main as well as the lateral corticospinal tracts 
(CSTs). The neutralizing antibodies to RGMa or the control 
rabbit IgGs were delivered via osmotic minipumps with cathe-
ters placed intrathecally near the thoracic injury site. There was 
no signifi  cant difference between the lesion depths in the con-
trol and treated groups (Fig. 4 A). The locomotor performance 
of the animals was monitored over a period of 9 wk after injury. 
The sham-operated rats (Fig. 4 B) achieved full scores accord-
ing to the Basso-Beattie-Bresnahan locomotor rating scale 
(BBB; Basso et al., 1995). All the spinally injured rats became 
almost completely paraplegic on the fi  rst day after the injury 
(Fig. 4 B) and then gradually displayed partial recovery of loco-
motor behavior as assessed by the BBB scores. There was no 
difference in the BBB scores of the anti-RGMa antibody– and 
control antibody–treated rats up to 4 wk after SCI. In fact, the 
locomotor performance from 6–9 wk after the surgery was sig-
nifi  cantly better in rats treated with the anti-RGMa antibody 
than in those treated with the control antibody. On average, rats 
treated with the control antibody attained a BBB score of 10.6, 
whereas those treated with the anti-RGMa antibody achieved a 
BBB score of 14.9 at 9 wk after the surgery. Thus, the anti-
RGMa antibody is effective in treating rats with SCI.
RGMa inhibition induces long-distance 
growth of injured ﬁ  ber tracts
The integrity of the dorsal CST in some previously tested rats 
was assessed by injecting biotin-dextran amine (BDA) into the 
bilateral sensory-motor cortices. For a group of animals (eight 
control and six anti-RGMa antibody–treated rats), blocks ex-
tending 5 mm rostral and 5 mm caudal to the center of the injury 
were sectioned in the sagittal plane (Figs. 5 and 6). The far ros-
tral as well as the far caudal segments were sectioned in the 
transverse plane (Fig. 7). For another group (three control and 
Figure 4.  The anti-RGMa antibody promotes locomotor recovery after SCI. 
(A) Quantiﬁ  cation of the lesion depth revealed that there was no statisti-
cally signiﬁ  cant difference between the control and anti-RGMa antibody–
treated animals. The signiﬁ  cance was determined by t test. Mean ± SEM 
of nine anti-RGMa antibody–treated and 11 control rats. (B) The BBB score 
was determined at the indicated times after thoracic dorsal hemisection 
in the anti-RGMa antibody–treated, control antibody–treated, and sham-
  operated rats. Mean ± SEM of 9, 11, and 5 rats for each group, respec-
tively. The anti-RGMa antibody–treated group is statistically different from 
the control group, as indicated. *, P < 0.05 compared with the control; 
**, P < 0.06 compared with the control.JCB • VOLUME 173 • NUMBER 1 • 2006  52
three anti-RGMa antibody–treated rats), the spinal cords were 
sectioned in the transverse plane (Fig. 7).
Samples from the injured rats treated with the anti-RGMa 
antibody exhibit a completely different pattern of labeling (Fig. 5, 
B and I–R; and Fig. S5, available at http://www.jcb.org/cgi/
content/full/jcb.200508143/DC1), as compared with those from 
the control antibody–treated rats (Fig. 5 A and Fig. S4, A–J). 
Proximal to the lesion, the main CST appears as a tight bundle 
of fi  bers, with the traced fi  bers neither entering nor growing be-
yond the lesion site in the control rats (Fig. 5, A, C, and E). This 
baseline pattern refl  ects that axonal regeneration does not nor-
mally occur in the CNS. In contrast, numerous ectopic fi  bers 
sprouting from the labeled CST were observed both rostral and 
caudal to the lesion site in rats that were treated with the anti-
RGMa antibody (Fig. 5, B and D). The longitudinal sections 
across the lesion site reveal lower retraction of the main CST 
bundles and a higher number of collateral CST sprouts in rats 
treated with the neutralizing antibody (Fig. 5, A and B; and 
Fig. 6 A). Regenerating fi  bers with typical irregular meandering 
growth patterns were frequently observed in the tissue bridges at 
the level of the lesion in rats treated with anti-RGMa anti-
body (Figs. 5, D and F; and Fig. S5, A and B). These regener-
ating fi  bers extended into the lesion scar, the gray matter caudal 
to the lesion, and along cysts (Fig. 5, F and H; and Fig. S3). 
Notably, many axons traversed the lesion tissue, thereby growing 
either around cavities or within the lesion epicenter, whereas no 
BDA-traced CST fi  bers could be detected in the control rats 
(Fig. 5 E). Bundles of axons extended through the lesion tissue and 
numerous labeled fi  bers were observed caudal to the lesion sites in 
the anti-RGMa antibody–treated rats (Figs. 5, G–K and M–R; and 
Figs. S3 and S5). In only one rat treated with the anti-RGMa anti-
body, however, did we not detect BDA-positive fi  ber in the scar 
tissue or caudal to the lesion site. Serial microscopic images 
(Fig. 5, I–R and Fig. S4, A–J) and camera lucida drawings of all 
the BDA-labeled fi  bers (Fig. S4, K and L) summarize the pattern 
of CST fi  ber growth in the rostral-caudal region of the injury. 
A few undamaged ventral fi  bers were illustrated in both cases.
We then reconstructed the serial sections of the injured 
spinal cords using all the 70–80 serial longitudinal sections per 
rat and estimated the number of the labeled fi  bers. In compari-
son with the number of labeled fi  bers observed 4 mm rostral to 
the lesioned site, >20% of the labeled fi  bers were seen in the 
caudal spinal cord of rats treated with the anti-RGMa antibody. 
However, only a small percentage of the fi  bers (1% at 1 mm 
caudal to the injury site) were seen in the control antibody–
treated rats (Fig. 6 B). Most of these fi  bers follow branched and 
tortuous courses, instead of a linear trajectory (Fig. 5 H; Fig. S3, 
B and C; Fig. S5, B, D, F, and H; and Video 1, available at 
Figure 5.  The anti-RGMa antibody promotes 
the regeneration/sprouting of CST axons after 
SCI. (A and B) Representative pictures of BDA-
labeled CST ﬁ  bers; rostral is on the left. Antero-
grade-labeled CST ﬁ  bers in control IgG–treated 
(A) or anti-RGMa antibody–treated (B) spinal 
cord 10 wk after injury. The epicenter of the le-
sion is indicated by an asterisk. (C–G) Higher 
magniﬁ  cation of the boxed regions in A and B, 
showing increased collateral CST ﬁ  ber sprout-
ing rostrally (D), as well as regenerating ﬁ  bers 
at the lesion site (F, arrows), in rats treated with 
the anti-RGMa antibody but not in the corre-
sponding regions of the control IgG–treated 
rats (C and E). (H) Different sections from the 
same animal (B), showing regenerating/
sprouting ﬁ  bers in the caudal part of the spinal 
cord. (I–R) Serial microscopic images of an 
anti-RGMa antibody–treated animal. Asterisks 
indicate the epicenter of the lesion. Arrows de-
note BDA-positive ﬁ  bers. Bars: (A, B, and I–R) 
500 μm; (C–F and H) 100 μm; (G) 200 μm.RGMA, A NOVEL INHIBITOR OF AXONAL REGENERATION • HATA ET AL. 53
http://www.jcb.org/cgi/content/full/jcb.200508143/DC1). At the 
caudal-most part of the regenerating fi  bers, we observed branches 
sprouting from the main tract (Fig. 5 G and Fig. S5 F).
We obtained cross-sections of the spinal cord and per-
formed a quantitative analysis of the distribution of the axons to 
exclude the possibility of axon sparing in the anti-RGMa anti-
body–treated rats. The total number of labeled fi  bers 10 mm 
above the lesion was almost identical between the anti-RGMa 
and control antibody–treated rats (Fig. 7, A, B, and I), indicat-
ing that the extent of BDA uptake was the same between the 
control and anti-RGMa antibody–treated rats. A thorough serial 
section reconstruction of the lesion site enabled us to conclude 
that there was no labeled CST axon that extended past the lesion 
in the normal locations of the dorsal CST in any of the rats 
(Fig. 7, C and D). In rats treated with the anti-RGMa antibody, 
however, BDA-positive fi  bers with tortuous appearance were 
detected in the scar tissue developing at the lesion site (Fig. 7, D 
and E). At 10 mm caudal to the lesion site, the sprouting axons 
extended through the gray matter to a greater extent than in 
the white matter in rats treated with the anti-RGMa antibody 
(Fig. 7, F–H and J–L). Almost no fi  bers were seen in the ventral 
part of the dorsal or dorsolateral column in the anti-RGMa anti-
body–treated rats as well as the control antibody–treated rats 
(Fig. 7, F and G [insets] and J). The fi  ber counts in the CST 
(Fig. 7 J) were not different from those in the negative control 
(non–BDA-labeled rats; not depicted). There was a little non-
specifi  c staining in the CST, which accounts for the few fi  ber 
counts in the CST (Fig. 7 J). These data strongly suggest that 
there were no spared CST axons, as axons that are spared and 
extend into the caudal segments should be present in their nor-
mal locations. Multiple fi  bers with tortuous appearance and un-
usual branching were seen in the gray matter in injured animals 
treated with the anti-RGMa antibody (Fig. 7, G, H, J, and L). 
In only one rat treated with the anti-RGMa antibody, however, did 
we not detect BDA-positive fi  ber at 1 mm caudal to the injury 
site. It should be noted that the labeling of the gray matter cau-
dal to the lesion site might be due to sprouting from undamaged 
ventral fi  bers. It is not possible to defi  nitely determine long-
tract regeneration. Our fi  ndings, however, met many of the cri-
teria for identifying regenerated axons (Steward et al., 2003) 
and raise the possibility that anti-RGMa antibody treatment 
promotes regrowth of injured CST axons.
Finally, we assessed whether the functional improvement is 
temporally correlated with the anatomical regeneration. We took 
consecutive sagittal sections of the spinal cords from anti-RGMa 
antibody–treated animals 3 and 5 wk after injury (n = 3 for each 
group). Fig. 8 shows representative pictures of BDA-labeled CST 
fi  bers in the control (Fig. 8, A and C) and anti-RGMa antibody–
treated animals (Fig. 8, B and D) 5 wk after injury. In anti-RGMa 
antibody–treated animals, the regenerating fi  bers extended into 
the lesion scar but did not extend into the caudal part of the spinal 
cord (Fig. 8, B and D). In the control rats, there was no labeled 
CST axon that extended past the lesion (Fig. 8, A and C). We re-
constructed the injured spinal cords and assessed the number of 
the labeled fi  bers (Fig. 8 E). 3 wk after injury, there was no sig-
nifi  cant difference between the fi  ber counts at any distance from 
the lesion site in anti-RGMa antibody– and control IgG–treated 
rats (Fig. 8 E). 5 wk after injury, a signifi  cant number of BDA-
positive fi  bers ( 25% as compared with the number observed 
4 mm rostral to the lesioned site) were detected at the lesion epi-
center in anti-RGM antibody–treated rats, whereas almost no 
 fi bers were seen in the control rats. These results suggest that 
functional improvement is temporally correlated with anatomical 
regeneration/sprouting in animals treated with anti-RGMa.
Discussion
The failure of axon regeneration in the spinal cord is at least 
partly attributable to the growth inhibitory properties of the 
CNS white matter and the scar tissue developing at the lesion 
site.   Several observations in this study established the notion that 
RGMa inhibits axon regeneration after SCI. RGMa inhibits neu-
rite outgrowth by activating the RhoA–Rho kinase signaling path-
way in vitro and is expressed by oligodendrocytes, myelin, and 
neurons in the adult rat CNS. After SCI, RGMa expression is in-
duced in the oligodendrocytes and microglia/macrophages around 
the injury site. The anti-RGMa antibody, which blocks the inhibi-
tory effect of RGMa and CNS myelin in vitro, enhances axonal 
regeneration/sprouting as well as functional recovery in vivo.
RhoA/Rho kinase and axon 
growth inhibition
Our data demonstrated that the inhibitory effect of RGM on the 
neurons is independent of the NgR and is mediated by the RhoA–
Rho kinase signaling pathway. This pathway is activated by three 
Figure 6.  Quantiﬁ  cation of the extent of regeneration/sprouting in anti-
RGMa antibody– and control IgG–treated rats. (A) The distance from the 
end of the main CST bundles to the lesion epicenter 10 wk after SCI in rats 
treated with the anti-RGMa antibody or control IgG (n = 6–8 per group). 
It was measured under low-magniﬁ  cation view of the longitudinal sections. 
*, P < 0.01 compared with the control. The anti-RGMa antibody sup-
presses the retraction of the injured main CST. (B) Quantiﬁ  cation of the la-
beled CST ﬁ  bers in six anti-RGMa antibody– and eight control IgG–treated 
animals. All the 50-μm-thick serial parasagittal sections were evaluated. 
The x axis indicates speciﬁ  c locations along the rostrocaudal axis of the 
spinal cord. The y axis indicates the ratio of the number of BDA-labeled ﬁ  -
bers at the indicated site to those at 4 mm rostral to the lesion site. *, P < 0.05 
compared with the control. Error bars indicate SEM.JCB • VOLUME 173 • NUMBER 1 • 2006  54
well-characterized myelin-associated inhibitors, Nogo, MAG, 
and OMgp, as well as CSPG, which are expressed both in the 
glial scar and in myelin (Mueller et al., 2005). Current evidence 
indicates that a common crucial signaling event for these myelin-
derived inhibitors of axon growth is the activation of RhoA. P75 
transduces the signal of the three myelin-derived inhibitors of 
axon regeneration by acting as a displacement factor that releases 
RhoA from Rho guanine dissociation inhibitor (Yamashita and 
Tohyama, 2003), which functions to maintain RhoA in an inac-
tive state by sequestering it in the cytoplasm and inhibiting the 
formation of active RhoGTP. Importantly, Dubreuil et al. (2003) 
demonstrated that SCI induces RhoA activation in both glial cells 
and neurons in vivo. They also found that immediate RhoA acti-
vation after SCI is p75 dependent but, thereafter, RhoA could be 
activated in a p75-independent manner. These observations sug-
gest the presence of other molecules that activate RhoA; this is 
consistent with our fi  ndings that RGMa activates RhoA and that 
its expression is induced around the injury site.
Expression of RGMa in the CNS
An immunohistochemical study of the normal spinal cord shows 
that RGMa is expressed by neurons and oligodendrocytes. 
This expression pattern in the spinal cord is similar to that of 
Nogo or OMgp (Hunt et al., 2002). In the injured spinal cord, 
however, the expression of RGMa around the lesion site is up-
  regulated; RGMa is expressed in the microglia/macrophages 
and oligodendrocytes at the injury site. Our recent report dem-
onstrates that, after SCI, RGMa is expressed by neurons, bal-
looned neurite fi  bers/retraction bulbs, oligodendrocytes, smooth 
muscle/endothelial cells, microglia/macrophages, leucocytes 
infi  ltrating the lesion, and with maturation of the lesion, cellular 
components (e.g., fi  broblastoid cells) and extracellular compo-
nents of the developing scar tissue (cicatrix; Schwab et al., 
2005a). In the human brain, a massive up-regulation of RGMa 
was observed at the lesioned or damaged site after focal cere-
bral ischemia or traumatic brain injury; RGMa was also present 
in the scar tissue (Schwab et al., 2005b). These observations 
suggest the important role of RGMa as an inhibitor of axon 
  regeneration in the injured adult mammalian CNS.
Functional recovery and axon 
regeneration after SCI
We observed an enhanced locomotor recovery by treatment 
with the anti-RGMa antibody after SCI. A delayed   improvement 
Figure 7.  Distribution of the regenerating/
sprouting CST ﬁ  bers in the spinal cord. (top) 
The injured spinal cord is illustrated schemati-
cally. (A–H) Representative transverse sections 
of the spinal cord taken from 10 mm rostral 
(A and B), 10 mm caudal (F–H), or adjacent 
(C–E) to the lesioned site from control IgG–
treated (A, C, and F) and anti-RGMa anti-
body–treated (B, D, E, G, and H) rats. Insets of 
A and B show the high-magniﬁ  cation view of 
the dorsal CST. (E) High-magniﬁ  cation view in 
D shows ﬁ  bers in the developing scar tissue at 
the lesion site. Insets of F and G illustrate that 
no ﬁ  bers are seen in the ventral part of the dor-
sal column (top right) or dorsolateral column 
(bottom right) 10 mm caudal to the lesion site. 
(H) High-magniﬁ   cation view in G shows in-
creased regenerated ﬁ   bers with tortuous ap-
pearance and unusual branching in the gray 
matter (inset) 10 mm caudal to the lesion site in 
rats treated with the anti-RGMa antibody. No 
labeled ﬁ  bers are observed 10 mm caudal to 
the lesion site in the corresponding region of 
the control IgG-treated rats (F). (I) The number 
of labeled corticospinal axons 10 mm rostral 
to the lesioned site in rats treated with the con-
trol IgG or anti-RGMa antibody. No signiﬁ  cant 
difference is observed. (J) The number of la-
beled corticospinal axons 10 mm caudal to the 
lesioned site in rats treated with the control IgG 
or anti-RGMa antibody. Cross-sections of the 
spinal cord taken from 10 mm caudal to the le-
sioned site were examined, and the number of 
the labeled ﬁ   bers was estimated in the gray 
matter (GM), the normal locations of the dorsal 
CST (CST), or the white matter other than the 
normal locations of the dorsal CST (WM). Data 
based on 11 control and 9 anti-RGMa anti-
body–treated rats. Increase in the regenerating 
ﬁ   bers caudal to the lesioned site in the anti-
RGMa antibody–treated rats is seen mainly in 
the gray matter. A small amount of nonspeciﬁ  c staining accounts for a few ﬁ  ber counts in the CST (no apparent BDA-positive ﬁ  bers were detected in this area). 
*, P < 0.01 compared with the control. (K and L) Camera lucida drawings illustrating the distribution of BDA-labeled ﬁ  bers in 10 serial sections from the 
cases illustrated in F and G, respectively. Bars: (A–D, F, and G) 500 μm; (A, B, F, and G, insets) 200 μm; (E) 50 μm; (H) 200 μm; (H, inset) 50 μm. RGMA, A NOVEL INHIBITOR OF AXONAL REGENERATION • HATA ET AL. 55
in locomotor recovery in the anti-RGMa antibody–treated rats 
might be related to the time course of RGMa expression, which 
was up-regulated after SCI.
We observed massive fi  ber growth by anti-RGMa anti-
body treatment in vivo, whereas the injured axons exhibited 
little, if any, sprouting in the spinal cord without the treatment. 
To exclude the possibility that the labeled fi  bers seen in the caudal 
portion of the spinal cord are spared axons, we performed thor-
ough reconstructions of the lesioned spinal cord by taking cross-
sections (Fig. 7). Multiple fi  bers with tortuous appearance and 
unusual branching patterns extended through the gray matter to 
a greater extent than in the white matter in the caudal portion 
of the spinal cords of rats treated with the anti-RGMa antibody. 
The labeled fi  bers in the gray matter 10 mm caudal to the lesion 
site are not collaterals of the dorsal CST, as most of the gray 
matter collaterals of the CST extend in the transverse plane and 
do not extend for long distances longitudinally through the gray 
matter (Steward et al., 2003). In fact, analysis of the serial sec-
tions of the lesion site from each rat revealed that there was no 
labeled CST axon that extended past the lesion in the normal 
locations of the dorsal CST. These fi  ndings strongly support 
our notion that the anti-RGMa antibody promotes regeneration 
and/or sprouting of injured CST fi  bers (Steward et al., 2003). 
However, it is not possible to defi  nitely determine long-tract 
regeneration. It is possible that the labeling in the gray matter 
caudal to the lesion site might be due to the sprouting from the 
undamaged ventral fi  bers. Evidence suggests that the ventral 
CST axons collaterally sprout into the gray matter after injury 
to the dorsal CST (Weidner et al., 2001). Treatment with a high 
dose of the Rho kinase inhibitor (Y29632), which enhanced 
functional recovery, induced an increase in the CST profi  les in 
the gray matter distal to the site of injury; this is indicative of 
collateral sprouting from the ventral spared CST axons (Chan 
et al., 2005). It is possible to induce the local reorganization of 
the central pattern generator circuitry, including sprouting from 
the undamaged ventral fi  bers, followed by enhanced functional 
recovery after SCI in anti-RGMa–treated animals.
Mutant mice lacking RGMa may also be useful in deter-
mining whether deletion of RGMa enhances the regeneration 
ability. However, as  50% of the mRGMa mutant mice show 
defects in cephalic neural tube closure (Niederkofl  er et al., 
2004), conditional knockout mice would be needed to ad-
dress this issue without considering the effect of RGMa in 
embryonic development.
Although there is some controversy concerning experi-
ments with targeted gene disruption of the myelin-associated 
inhibitors, treatments with some neutralizing agents have shown 
effi  cacy in promoting regeneration in animal SCI. Similar to our 
fi  ndings in anti-RGMa antibody treatment, treatment with the 
anti–Nogo A antibody induces regeneration after rat SCI 
(Bregman et al., 1995). A peptide antagonist, NEP1-40, which 
competes for binding of Nogo-66 to the NgR, has also shown 
signifi  cant effi  cacy in terms of promoting regeneration in SCI 
models (GrandPre et al., 2002; Teng and Tang, 2005). Thus, 
neutralizing agents including the anti-RGMa antibody may 
have the potential for clinical applications against SCI (Teng 
and Tang, 2005).
Signaling mechanism of RGMa
Neogenin is a high-affi  nity receptor for RGM, mediating its re-
pulsive activity for retinal axons (Rajagopalan et al., 2004). 
It was recently reported that RGMa mediates BMP signaling by 
acting as a coreceptor via Smad 1, 5, and 8 and up-regulates the 
endogenous inhibitor of differentiation (Id1) protein (Babitt 
et al., 2005). An interaction of RGMa with neogenin along with 
BMP type I receptor or as a homophilic interaction by itself, as 
reported for RGMb (dragon; Samad et al., 2004), might under-
lie its inhibitory activity toward the regeneration of CST fi  bers. 
Figure 8.  Anatomical analysis of the spinal cords 3 and 5 wk after SCI. 
(A and B) Representative pictures of anterograde-labeled CST ﬁ  bers in rat 
spinal cord treated with the control IgG (A) or anti-RGMa antibody (B) 5 wk 
after injury; rostral is on the left. Asterisks indicate the lesion epicenter. 
Higher magniﬁ  cation of the boxed regions in A and B, showing regenerat-
ing ﬁ  bers, with typical irregular meandering growth patterns around the 
cysts at the lesion site (D) in rats treated with the anti-RGMa antibody but 
not in the corresponding regions of the control IgG–treated rats (C). In both 
the groups, no BDA-traced ﬁ  bers could be observed in the caudal part of 
the spinal cord 5 wk after injury. (E) Quantiﬁ  cation of the labeled CST 
  ﬁ  bers in the anti-RGMa antibody–treated animals 3 wk (n = 3) and 5 wk 
(n = 3) after injury and in the control IgG–treated animals 3 wk (n = 3) 
and 5 wk (n = 3) after injury. All the 50-μm-thick serial parasagittal sections 
were evaluated. The x axis indicates speciﬁ  c locations along the rostrocau-
dal axis of the spinal cord. The y axis indicates the ratio of the number 
of BDA-labeled ﬁ  bers at the indicated site to those at 4 mm rostral to the 
  lesion site. *, P < 0.05 compared with the control (5W). Bars: (A and B) 
500 μm; (C and D) 100 μm.JCB • VOLUME 173 • NUMBER 1 • 2006  56
A clarifi  cation of the precise signaling cascade of the RGMa is 
expected to contribute to the development of more effective 
therapies for the treatment of adult mammalian CNS injuries.
In summary, our results demonstrate that RGMa is an im-
portant inhibitory molecule for successful neuroregeneration in 
vivo and suggest that its manipulation would be useful for the 
treatment of human spinal injuries.
Materials and methods
Plasmid constructs
Because the previous report (Monnier et al., 2002) has shown that native 
chick and functionally active RGM starts with residue 152, we created an 
HA-RGMa vector in pSecTag2-Hygro (Invitrogen) using the signal peptide 
of pSecTag2 fused to HA and residues 152–431 of rat RGMa (available 
from GenBank/EMBL/DDBJ, under accession no. XP_218791). FPC-1-
MAG-Fc– and MAG-Fc–expressing CHO cells are gifts from M. Endo and 
K. Mizuno (Tohoku University, Sendai, Japan).
Generation of RGMa-CHO cells
Flp-in system (Invitrogen) was used to generate RGMa-expressing cells 
  according to the manufacturer’s recommendations. We generated an HA-
RGMa fragment containing a signal peptide from pSecTag2 vector using 
two restriction endonucleases and ligated it into pcDNA5FRT (Invitrogen). 
This construct (pcDNA5FRT/Igκleader/HA/RGMa) and pOG44 were co-
transfected into Flp-in CHO cells, and stable expressing cells were gener-
ated after growth in medium containing 500 μg/ml Hygromycin B 
(Invitrogen) for 2 wk. Expression of HA-RGMa was conﬁ  rmed by immuno-
detection using Western blots and immunocytochemistry. We also gener-
ated human RGMa–expressing cells and conﬁ   rmed that human RGMa, 
either membrane bound or diffusible, potently inhibits the neurite outgrowth 
of postnatal cerebellar granule neurons.
Neurite outgrowth assay
Cerebellar granule cells from rat pups at postnatal days 7–9 were dissoci-
ated by trypsinization (0.25% trypsin in PBS for 15 min at 37°C) followed 
by resuspension in serum-containing medium, trituration, and wash with 
PBS three times. Cultures were grown in a serum-free DME/F12 medium. 
For the coculture assay, neurons were plated on conﬂ  uent monolayers of 
either RGMa-CHO or control CHO cells in chamber slides (LabTek II; 
Nunc). For the soluble RGMa assay, conﬂ  uent monolayers of either RGMa-
CHO or control CHO cells were incubated in serum-free DME/F12 
medium with or without 2.5 U/ml PI-PLC (Sigma-Aldrich) at 37°C for 3 h. 
Those treated CHO cells were subjected to the coculture assay. After cen-
trifugation of the culture media at 13,000 g for 10 min, the supernatants 
were collected to remove ﬂ  oating cells. A part of the supernatants was sub-
jected to SDS-PAGE and Western blot analysis to estimate concentration of 
soluble RGMa with various amounts of the standards (recombinant RGM-A; 
R&D Systems). Estimated concentration of soluble RGMa was 1.37 
(± 0.13 SEM) μg/ml. Neurons were plated in the conditioned media on 
PLL-coated chamber slides and were incubated for 12 or 24 h. Where 
  indicated, 10 μM of Y27632 (Mitsubishi Pharmaceuticals) was added to 
the cultures. To inhibit the NgR, 1 μM of NEP(1–40) (Sigma-Aldrich) was 
added to the culture. For neutralizing antibody assay, anti-RGMa antibody 
or control rabbit IgG was added to the culture at the concentration of 
10 μg/ml. For the neurite outgrowth assay on myelin, we performed myelin 
preparation from rat brain as described previously (Norton and Padulso, 
1973). 3 μg/well of the puriﬁ  ed myelin or the depleted myelin were used 
to coat PLL-coated eight-well chamber slides (Benson et al., 2005). The 
cells were ﬁ   xed in 4% (wt/vol) paraformaldehyde and were immuno-
stained with a monoclonal antibody recognizing TuJ1 (1:1,000; Covance). 
The length of the longest neurite for each β tubulin III–positive neuron was 
then determined.
Afﬁ  nity precipitation of GTP-RhoA
Cells were lysed in 50 mM Tris, pH 7.5, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, 500 mM NaCl, and 10 mM MgCl2, with leu-
peptin and aprotinin, each at 10 μg/ml. Cell lysates were clariﬁ  ed by cen-
trifugation at 13,000 g at 4°C for 10 min, and the supernatants were 
incubated with the 20 μg of GST-Rho binding domain of Rhotekin beads 
(Upstate Biotechnology) at 4°C for 45 min. The beads were washed four 
times with washing buffer (50 mM Tris, pH 7.5, containing 1% Triton 
X-100, 150 mM NaCl, 10 mM MgCl2, and 10 μg/ml each of leupeptin 
and aprotinin). Bound Rho proteins were detected by Western blotting using 
a monoclonal antibody against RhoA (Santa Cruz Biotechnology, Inc.).
Immunodepletion of RGMa
To examine the remaining effect of myelin-derived inhibitors except RGMa 
on neurite outgrowth, we subjected the sample to four rounds of immuno-
depletion (McKerracher et al., 1994). The puriﬁ  ed myelin was extracted 
with 20% octylglucoside salt (Dojindo). The extract was centrifuged at 
40,000 g for 60 min, and the supernatant was incubated with the 20 μg 
of anti-RGMa antibody overnight at 4°C. 50 μg of protein A beads were 
added for 3 h with rotation and centrifuged, and the supernatant was sub-
jected to three repeat treatments. The ﬁ  nal depleted samples and the pro-
tein A beads were subjected to SDS-PAGE and Western blot analysis, and 
bioassays were performed as described (see Neurite outgrowth assay).
Western blot analysis
CHO cells, cerebellar granule neurons, or adult rat spinal cords were lysed 
in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, and 0.5% Brij-58 
(Sigma-Aldrich), including protease inhibitor cocktail tablets (Roche 
  Diagnostics). The lysates were clariﬁ  ed by centrifugation at 13,000 g at 
4°C for 10 min, and the supernatants were collected and normalized for 
protein concentration. Equal amounts of protein were then boiled in sam-
ple buffer containing 12% β-mercaptoethanol for 5 min and subjected to 
SDS-PAGE. The conditioned media, puriﬁ  ed myelin, MAG-Fc, and CSPG 
(Chemicon) were also treated in the same manner except for the lysis buffer 
treatment. MAG-Fc was puriﬁ  ed from stable expressing cells (provided by 
K. Mizuno). The proteins were transferred onto polyvinylidene diﬂ  uoride 
membrane and incubated with 1 μg/ml of a polyclonal anti-RGMa anti-
body, a monoclonal anti-HA antibody (1:1,000; Sigma-Aldrich), a poly-
clonal anti-neogenin antibody (1:1,000; Santa Cruz Biotechnology, Inc.), 
or a polyclonal anti-actin antibody (1:1,000; Santa Cruz Biotechnology, 
Inc.). For detection, an ECL chemiluminescence system (GE Healthcare) 
and HRP-conjugated secondary antibodies (1:1,000; Cell Signaling Tech-
nology) were used.
Anti–rat RGMa antibody production
The domain important for functional activity in chick RGM is the COOH-
  terminal 150–200 amino acids of the active RGM protein. A synthetic 
peptide (residues 309–322) was selected as immunogen to generate anti–
rat RGMa rabbit antisera. The sequence of the peptide is speciﬁ  c to rat 
RGMa but has no similarity with RGMb or -c. Antisera were afﬁ  nity puriﬁ  ed 
and used at 1 μg/ml for immunohistochemistry and immunoblots and at 
10 μg/ml for neutralizing antibody assay. To assess the speciﬁ  city of the 
anti-RGMa antibody, control and SCI sections were stained in the presence 
of the rat RGMa–speciﬁ  c peptide (residues 309–322; Fig. S2). An addi-
tional control experiment was done by leaving out the primary antibody. 
These experiments conﬁ  rmed the speciﬁ  city of the anti-RGMa antibody.
Surgical procedure
Anesthetized (sodium pentobarbital, 40 mg/kg) female Wistar rats (200–
250 g) received a laminectomy at vertebral level T9/10, and the spinal 
cord was exposed. A number 11 blade was used to cut the dorsal part of 
the spinal cord at a depth of 1.8 mm. Histologic examination has revealed 
that these lesions sever all dorsal CST ﬁ  bers in the dorsal funiculus as well 
as the lateral CST and extend past the central canal in all animals. For 
neutralizing antibody assay in animal model, immediately after the spinal 
cord hemisection, rats were ﬁ  tted with an osmotic minipump (200 μl solu-
tion, 0.5 μl/h, 14-d delivery; Alzet pump model 2002 [Durect Co.]) ﬁ  lled 
with control rabbit IgG (17 animals, 22.3 μg/kg/day over 2 wk; Sigma-
Aldrich) or anti-RGMa antibody (15 animals, 22.3 μg/kg/day over 
2 wk). The minipump was placed under the skin on the animal’s back, and 
a silastic tube connected to the outlet of the minipump was placed under 
the dura at the spinal cord hemisection site with the tip lying immediately 
rostral to the injury site. The tube was sutured to the spinous process just 
caudal to the laminectomy to anchor it in place. Afterward, the muscle and 
skin layers were sutured. The bladder was expressed by manual abdomi-
nal pressure at least twice a day until bladder function was restored. 
Sham-operated rats (ﬁ   ve animals) received a laminectomy at vertebral 
level T9/10, and the spinal cords were exposed. The muscle and skin 
  layers were then sutured.
Tissue preparation and immunohistochemistry
For immunohistochemistry, fresh frozen tissues were obtained from an un-
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  After deep anesthesia with diethyl ether, the rats were decapitated and the 
spinal cords dissected out, embedded in Tissue Tek OCT, and immediately 
frozen on dry ice at −80°C. Series of parasagittal sections as well as cross-
sections were cut at 18 or 50 μm on a cryostat and mounted on APS coating 
Superfrost-Plus slides (Matsunami). The sections were ﬁ  xed in 4% (wt/vol) 
paraformaldehyde for 1 h at room temperature, washed three times with 
PBS, and blocked in PBS containing 5% goat serum and 0.1% Triton X-100 
for 1 h at room temperature. The sections were incubated with primary an-
tibodies overnight at 4°C and washed three times with PBS, followed by 
  incubation with ﬂ   uorescein-conjugated secondary antibodies (1:1,000; 
  Invitrogen) for 1 h at room temperature. 1 μg/ml of polyclonal anti-RGMa 
antibody, monoclonal anti-GFAP (1:1,000; Sigma-Aldrich), monoclonal 
anti-MOSP (1:500; Chemicon), or monoclonal antibody recognizing TuJ1 
(1:1,000; Covance) was used as the primary antibody. For double labeling 
of IB4 from Griffonia simplicifolia (1:100; Vector Laboratories) and RGMa, 
the animals were killed by perfusion with PBS followed by 4% paraformal-
dehyde. The spinal cords were dissected, postﬁ  xed, and heated. Samples 
were examined under a confocal laser-scanning microscope (Carl Zeiss 
  MicroImaging, Inc.) with 4×, 10×, 20×, 40×, and 63× objectives.
Anterograde labeling of the CST
1 wk (three control and three anti-RGMa antibody–treated rats), 3 wk (three 
control and three anti-RGMa antibody–treated rats), or 8 wk (11 control 
and 9 anti-RGMa antibody–treated rats) after injury, descending CST ﬁ  bers 
were labeled with BDA (10% in saline, 3.5 μl per cortex, MW 10,000; 
  Invitrogen) injected under anesthesia at the left and the right motor cortices 
(coordinates: 2 mm posterior to bregma, 2 mm lateral to bregma, 1.5 mm 
depth). For each injection, 0.25 μl of BDA was delivered for a period of 
30 s via a 15–20-μm inner diameter glass capillary attached to a microliter 
syringe (ITO). In total, we examined and compared the regenerative re-
sponses of 17 control and 15 anti-RGMa antibody–treated rats after SCI. 
14 d after BDA injection, the animals were killed by perfusion with PBS fol-
lowed by 4% paraformaldehyde. The spinal cords were dissected, post-
ﬁ  xed overnight in the same ﬁ  xatives, and cryopreserved in 30% sucrose in 
PBS. The spinal cord 5 mm rostral and 5 mm caudal to the lesion site (10 mm 
long) was embedded in Tissue Tek OCT. These blocks were sectioned in the 
sagittal plane (50 μm) or in the transverse plane, retaining each section. 
In both cases, transverse sections were also collected from the spinal cord 
>5 mm rostral and caudal to the injury site (17 control and 15 anti-RGMa 
antibody–treated rats). Sections were blocked in PBS with 0.5% BSA for 
1 h and then incubated for 1 d with Alexa Fluor 488–conjugated streptavidin 
(1:400; Invitrogen) in PBS with 0.15% BSA.
Quantiﬁ  cation
To reconstruct serial parasagittal sections completely, all serial 50-μm-thick 
sections ( 70–80 sections per animal; eight control and six anti-RGMa 
antibody–treated rats in Fig. 6 B, six control and six anti-RGMa antibody–
treated rats in Fig. 8 E) were evaluated. On each section, the number of in-
tersections of BDA-labeled ﬁ  bers with a dorsoventral line was counted from 
4 mm above to 4 mm below the lesion site. Axon number was calculated 
as a percentage of the ﬁ  bers seen 4 mm above the lesion, where the CST 
was intact. The distance beyond the epicenter of the lesion was scored as 
positive and otherwise as negative distance.
The distance from the end of the main CST bundles to the lesion epi-
center was measured for each animal for quantiﬁ  cation of the retraction of 
CST ﬁ  bers. The distance beyond the epicenter of the lesion was scored as 
positive and otherwise as negative distance.
To exclude the possibility of axon sparing in the anti-RGMa anti-
body–treated rats, we took thorough serial cross-sections of the spinal cord 
and performed quantitative analysis of the distribution of the axons (11 
control and 9 anti-RGMa antibody–treated rats). Degrees of BDA uptake 
were assessed by counting the total number of ﬁ  bers in the cross-section 
10 mm rostral to the lesioned site. For quantiﬁ  cation of the number of labeled 
corticospinal axons 10 mm caudal to the lesion site, the number of the la-
beled ﬁ  bers was measured for each animal in the gray matter, the dorsal 
CST area (normal locations of the dorsal CST), or the white matter except 
the dorsal CST area, divided by the number of labeled corticospinal axons 
10 mm above the lesion.
For camera lucida drawing, all consecutive parasagittal sections 
from 4 mm above to 4 mm below the injury site or transverse sections 
around 10 mm caudal the lesion site were imaged, and BDA-positive CST 
axons were traced.
Behavioral testing
Behavioral recovery was assessed for 9 wk after injury in an open ﬁ  eld en-
vironment by the BBB. Uninjured and sham-operated rats (n = 5) achieved 
full scores. Quantiﬁ  cation was performed in a blinded manner by two (the 
ﬁ  rst group; eight control and six anti-RGMa antibody–treated rats) or three 
(the second group; three control and three anti-RGMa antibody–treated rats) 
observers. The difference of judged counts among the observers was within 
1 point on the BBB scoring scale.
Online supplemental material
Fig. S1 demonstrates that cerebellar granule neurons express neogenin. 
Fig. S2 shows speciﬁ  city of the anti-RGMa antibody. Fig. S3 shows regen-
erated CST axons with the anti-RGMa antibody treatment. Fig. S4 displays 
serial microscopic images of a control IgG–treated rat and reconstruction 
of the lesioned spinal cords treated with control IgG or the anti-RGMa anti-
body. Fig. S5 shows injured spinal cords of four animals with anti-RGMa 
antibody treatment. Video 1 shows regenerated CST axons with the anti-
RGMa antibody treatment. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200508143/DC1.
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